Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients
References
- 1. Agarwal R. et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med., 115, 291, 2003.
- 2. Aldamiz-Echevarria L., Andrade F.: Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci.,13, 11288, 2012.
- 3. Alsagaff M.Y. et al.: Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J. Int. Med. Res., 40, 340, 2012.
- 4. Arici M., Walls J.: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int., 59, 407, 2001.
- 5. Bassareo P.P. et al.: Urinary NGAL and hematic ADMA levels: an early sign of cardio-renal syndrome in young adults born preterm? J. Matern. Fetal Neonatal Med., 26, 80, 2013.
- 6. Bassareo P.P. et al.: Could ADMA levels in young adults born preterm predict an early endothelial dysfunction? Int. J. Cardiol., 159, 217, 2012.
- 7. De Jager D.J. et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA, 302, 1782, 2009.
- 8. Goonasekera C.D. et al.: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens., 15, 901, 1997.
- 9. Guerin A, Pannier B, London G.: Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol.,44, 187, 2007.
- 10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 39, 1, 2002.
- 11. Kielstein J.T. et al.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc.Nephrol., 13, 170, 2002.
- 12. Kielstein J.T. et al.: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol., 10, 594, 1999.
- 13. Kielstein J.T. et al.: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res., 27, 143, 2004.
- 14. Koch M. et al.: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant., 12, 1187, 1997.
- 15. Luyckx V.A., Brenner B.M. Low birth weight, nephron number and kidney disease. Kidney Int., 97, 68, 2005.
- 16. Mallamaci F. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol., 15, 435, 2004.
- 17. Nakayama Y. et al.: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int., 9, 1, 2013.
- 18. Perticone F. et al.: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol., 142, 236, 2010.
- 19. Raptis V., Kapoulas S., Grekas D.: Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton), 18, 11, 2013.
- 20. Rocha M.S. et al.: Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis, 222, 509, 2012.
- 21. Rodriguez M.M. et al.: Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr. Nephrol., 20, 945, 2005.
- 22. Rutkowski B. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2009. Drukonsul, Gdańsk 2010.
- 23. Sarnak M.J., Levey A.S.: Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J. Thromb. Thrombolysis, 10, 169, 2000.
- 24. Schwarz P. et al.: Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ. Res., 77, 841, 1995.
- 25. Sesti G. et al.: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Atherosclerosis, 231, 141, 2013.
- 26. Sibal L. et al.: The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol.Rev., 6, 82, 2010.
- 27. Sydow K. et al.: Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem., 56, 111, 2010.
- 28. Tripepi G. et al.: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.Clin. J. Am. Soc. Nephrol., 6, 1714, 2011.
- 29. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
- 30. Ueda S. et al.: Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology, 12, 582, 2007.
- 31. Wilcken D.E. et al.: Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol. Genet. Metab., 91, 309, 2007.
- 32. Zoccali C. et al.: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am.Soc. Nephrol., 13, 490, 2002.
- 33. Zoccali C. et al:. Inflammation is associated with carotid atherosclerosis in dialysis patients. J. Hypertens., 18, 1207, 2000.
Language: English
Page range: 37 - 40
Submitted on: Feb 13, 2014
Accepted on: Mar 6, 2014
Published online: May 30, 2014
Published in print: Jun 1, 2014
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Related subjects:
© 2014 Marcin Dziedzic, Ewelina Orlowska, Kinga Gawel, Magdalena Zawadzka, Anna Bednarek-Skublewska, Janusz Solski, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.